Cue Health Inc.
Healthcare · Laboratory Analytical Instruments · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
| Revenue | $70.9M | $483.5M | $618.1M | $23.0M | $6.6M |
| Operating income | −$394.9M | −$205.7M | $190.2M | −$45.1M | −$20.8M |
| Net income | −$373.5M | −$194.1M | $86.4M | −$47.4M | −$20.6M |
| Total assets | $339.8M | $694.6M | $940.1M | $316.3M | — |
| Total liabilities | $89.5M | $118.1M | $233.3M | $241.4M | — |
| Equity | $250.3M | $576.5M | $706.8M | −$101.4M | −$58.1M |
| EPS (diluted) | $-2.44 | $-1.31 | $0.59 | $-2.90 | $-1.31 |
| Shares out. | 151.4M | 146.6M | 146.4M | 28.0M | 15.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −556.6%
- Net margin
- −526.5%
- Return on equity
- −149.2%
- Return on assets
- −109.9%
- Return on capital (ROCE)
- −133.3%
- Liabilities / assets
- 26.4%
- Debt / equity
- 0.36×
- Book value / share
- $1.65
- Revenue growth (YoY)
- −85.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -9.26distress
- Accruals / assets
- −69.4%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 16, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Tarsadia Capital, Llc10% owner | Aug 23, 2024 | Sell | 10.7M | $0.00 |
| Sever ClintOfficer — Chief Executive Officer | Mar 25, 2024 | Tax withholding | 20,456 | $0.19 |
| Pollard Randall E.Officer — Chief Accounting Officer | Mar 5, 2024 | Tax withholding | 7,304 | $0.25 |
| Achar Christopher KDirector | Mar 5, 2024 | Tax withholding | 8,482 | $0.25 |
| Javed AasimOfficer — Chief Financial Officer | Mar 5, 2024 | Tax withholding | 13,327 | $0.25 |
| Sever ClintOfficer — Chief Product Officer | Mar 5, 2024 | Tax withholding | 12,604 | $0.25 |
| Khattak Ayub KOfficer — President and CEO | Mar 5, 2024 | Tax withholding | 10,742 | $0.25 |
| Achar Christopher KDirector | Feb 8, 2024 | Grant | 300,000 | $0.00 |
| Pollard Randall E.Officer — Chief Accounting Officer | Feb 8, 2024 | Grant | 200,000 | $0.00 |
| Javed AasimOfficer — Chief Financial Officer | Feb 8, 2024 | Grant | 300,000 | $0.00 |
| Sever ClintOfficer — Chief Product Officer | Feb 8, 2024 | Grant | 500,000 | $0.00 |
| Khattak Ayub KOfficer — President and CEO | Feb 8, 2024 | Grant | 700,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Bankruptcy or receivership · Delisting / listing-standard notice · Director / officer change · Regulation FD disclosureMay 28, 2024
- Director / officer change · Shareholder vote · Other material eventMay 16, 2024
- Costs from exit or disposalMay 1, 2024
- Director / officer changeApr 24, 2024
- Entered a material agreement · Modified shareholder rights · Other material eventApr 9, 2024
- Director / officer changeMar 29, 2024
- Director / officer changeMar 20, 2024
- Results of operationsMar 13, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.